Skip to main content
main-content

01.09.2017 | Original Article | Ausgabe 1/2018

Comparative Clinical Pathology 1/2018

Apoptosis induced by Moringa oleifera Lam. pod in mouse colon carcinoma model

Zeitschrift:
Comparative Clinical Pathology > Ausgabe 1/2018
Autoren:
Suchada Kraiphet, Chaniphun Butryee, Anudep Rungsipipat, Sirintip Budda, Kasem Rattanapinyopitak, Siriporn Tuntipopipat

Abstract

The aim of this study was to investigate the effect of boiled Moringa oleifera Lam. pod (bMO) in colon carcinogenesis via apoptotic pathway. Four groups of mice (eight mice/group) were induced by azoxymethane (AOM, 10 mg/kg BW i.p. at the third week) followed by dextran sodium sulfate (DSS) for 7 days (2% in drinking water at the fourth week), while one negative group (n = 8) received AIN-76A basal diet without AOM/DSS induction. Positive control group received basal diet with AOM/DSS induction, whereas treatment groups received basal diet containing 1.5%, 3.0%, and 6.0% of bMO at the 5th week till 20th week after AOM/DSS inductions. Mice were sacrificed and necropsied at the end of the 20th week. The results showed tumor incidence 87.5% and multiplicity 9.5 in positive control group. Subsequently, mice that received 1.5%–6.0% bMO exhibited tumor incidences and multiplicities at 25%–75% and 1.8–8.3, respectively. Pro-apoptosis protein BAX investigated by immunohistochemistry in mice treated with 3.0% bMO was significantly higher than positive control. Anti-apoptosis protein BCL-2 showed the lowest expression in mice fed with 6.0% bMO. The BAX/BCL-2 ratio proteins and the nuclear staining were found at the highest rate in mice received 3.0% bMO. This finding suggested that the bMO exhibited potent apoptosis induction through dissimilarity of BCL-2 family protein expression, thereby decreased BCL-2 protein expression and increased the BAX protein to promote cell death. Therefore, bMO has a potential as chemotherapeutic agent in colon cancer through induction of apoptosis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Comparative Clinical Pathology 1/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

01.10.2020 | Magenkarzinom | Schwerpunkt: In-situ-Hybridisierung | Ausgabe 6/2020

ISH-basierte HER2-Diagnostik

30.09.2020 | Schwerpunkt: In-situ-Hybridisierung | Ausgabe 6/2020

RNA-in-situ-Hybridisierung: Technologie, Möglichkeiten und Anwendungsbereiche

28.09.2020 | Lungenkarzinome | Schwerpunkt: In-situ-Hybridisierung | Ausgabe 6/2020

Anwendungen der FISH in der Diagnostik von Lungenkarzinomen